@article{dee915b0af964ec2abbb2f105e5e9517,
title = "APOE4 Allele, Sex, and Dementia Risk in Parkinson{\textquoteright}s Disease: Lessons From a Longitudinal Cohort",
abstract = "Introduction: The effect of APOE4 allele on dementia risk is well established in Alzheimer{\textquoteright}s disease and Parkinson{\textquoteright}s disease (PD). However, it is unknown if sex modifies this relationship. We sought to determine the effect of sex on the relationship between APOE4 status and incident cognitive decline in PD. Methods: Data from the prospectively collected longitudinal National Alzheimer{\textquoteright}s Coordinating Center (NACC) Uniform Data Set (UDS) and Neuropathology Data Set (NDS) were analyzed. The NACC develops and maintains data from approximately 29 National Institutes of Aging-funded Alzheimer's Disease Research Centers. Further details may be found at the NACC web site (www.alz.washington.edu). The visit at which diagnosis of PD was made was termed the baseline visit. All patients with a PD diagnosis but without dementia at the baseline visit were included in the analyses. Results: Presence of APOE4 allele was associated with higher odds (OR = 7.4; P <.001) of subsequent diagnosis of dementia and with a faster time to developing dementia (P =.04). Those with APOE4 allele were more likely to have neuropathology associated with Alzheimer{\textquoteright}s disease than those without APOE4 allele. We did not find any difference by sex. There were no differences between Lewy body pathology or neuron loss in the substantia nigra between the 2 groups. Sex was not associated with dementia risk in PD (OR = 0.53, P =.15) or with the time to dementia onset (P =.22). Sex did not modify the relationship between the APOE4 allele and dementia onset in PD patients (P =.12) Conclusions: APOE4 allele status in PD may be a predictor of cognitive decline in PD but does not appear to be modified by sex.",
keywords = "APOE4, Parkinson{\textquoteright}s disease, dementia, sex",
author = "Umeh, {Chizoba C.} and Abhimanyu Mahajan and Aleksandra Mihailovic and Pontone, {Gregory M.}",
note = "Funding Information: Dr. Umeh{\textquoteright}s mentorship for this project was facilitated by the Parkinson Study Group, Visiting Mentorship Award, sponsored by Sunovion Pharmaceuticals. She reports no conflicts of interest. Dr. Mahajan has received funding from the Dystonia Medical Research Foundation, Sunflower Parkinson{\textquoteright}s disease Foundation, and the Parkinson{\textquoteright}s Foundation outside of the submitted work. He reports no conflicts of interest. Ms. Mihailovic reports no disclosures or conflicts of interest. Dr. Pontone is a consultant for Acadia Pharmaceuticals Inc and receives funding from the NIH/NIA as a co-investigator for a multicenter, randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AGB101 (levetiracetam) on slowing progression of amnestic mild cognitive impairment due to Alzheimer{\textquoteright}s disease (HOPE4MCI) R01AG048349 and Longitudinal Molecular Imaging of Neuropathology and Serotonin in Mild Cognitive Impairment R01AG059390. Funding Information: The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA-funded ADCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P30 AG062428-01 (PI James Leverenz, MD) P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P50 AG047266 (PI Todd Golde, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P30 AG062421-01 (PI Bradley Hyman, MD, PhD), P30 AG062422-01 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Thomas Wisniewski, MD), P30 AG013854 (PI Robert Vassar, PhD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P50 AG047366 (PI Victor Henderson, MD, MS), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P30 AG062429-01(PI James Brewer, MD, PhD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG053760 (PI Henry Paulson, MD, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P30 AG049638 (PI Suzanne Craft, PhD), P50 AG005136 (PI Thomas Grabowski, MD), P30 AG062715-01 (PI Sanjay Asthana, MD, FRCP), P50 AG005681 (PI John Morris, MD), P50 AG047270 (PI Stephen Strittmatter, MD, PhD). The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Dr. Umeh's mentorship for this project was facilitated by the Parkinson Study Group, Visiting Mentorship Award, sponsored by Sunovion Pharmaceuticals. Funding Information: The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Dr. Umeh's mentorship for this project was facilitated by the Parkinson Study Group, Visiting Mentorship Award, sponsored by Sunovion Pharmaceuticals. Funding Information: The NACC database is funded by NIA/NIH Grant U01 AG016976. NACC data are contributed by the NIA-funded ADCs: P30 AG019610 (PI Eric Reiman, MD), P30 AG013846 (PI Neil Kowall, MD), P30 AG062428-01 (PI James Leverenz, MD) P50 AG008702 (PI Scott Small, MD), P50 AG025688 (PI Allan Levey, MD, PhD), P50 AG047266 (PI Todd Golde, MD, PhD), P30 AG010133 (PI Andrew Saykin, PsyD), P50 AG005146 (PI Marilyn Albert, PhD), P30 AG062421-01 (PI Bradley Hyman, MD, PhD), P30 AG062422-01 (PI Ronald Petersen, MD, PhD), P50 AG005138 (PI Mary Sano, PhD), P30 AG008051 (PI Thomas Wisniewski, MD), P30 AG013854 (PI Robert Vassar, PhD), P30 AG008017 (PI Jeffrey Kaye, MD), P30 AG010161 (PI David Bennett, MD), P50 AG047366 (PI Victor Henderson, MD, MS), P30 AG010129 (PI Charles DeCarli, MD), P50 AG016573 (PI Frank LaFerla, PhD), P30 AG062429-01(PI James Brewer, MD, PhD), P50 AG023501 (PI Bruce Miller, MD), P30 AG035982 (PI Russell Swerdlow, MD), P30 AG028383 (PI Linda Van Eldik, PhD), P30 AG053760 (PI Henry Paulson, MD, PhD), P30 AG010124 (PI John Trojanowski, MD, PhD), P50 AG005133 (PI Oscar Lopez, MD), P50 AG005142 (PI Helena Chui, MD), P30 AG012300 (PI Roger Rosenberg, MD), P30 AG049638 (PI Suzanne Craft, PhD), P50 AG005136 (PI Thomas Grabowski, MD), P30 AG062715-01 (PI Sanjay Asthana, MD, FRCP), P50 AG005681 (PI John Morris, MD), P50 AG047270 (PI Stephen Strittmatter, MD, PhD). Publisher Copyright: {\textcopyright} The Author(s) 2021.",
year = "2022",
month = nov,
doi = "10.1177/08919887211060019",
language = "English (US)",
volume = "35",
pages = "810--815",
journal = "Journal of Geriatric Psychiatry and Neurology",
issn = "0891-9887",
publisher = "SAGE Publications Inc.",
number = "6",
}